The Journal of Urology
Volume 182, Issue 1 , Pages 29-34 , July 2009

Sequential Sorafenib and Sunitinib for Renal Cell Carcinoma

  • M.P. Sablin

      Affiliations

    • Institut Gustave Roussy, Villejuif, France
    • ,
  • S. Negrier

      Affiliations

    • Centre Léon Bérard, Lyon, France
    • ,
  • A. Ravaud

      Affiliations

    • Hôpital Saint-André, Bordeaux, France
    • ,
  • S. Oudard

      Affiliations

    • Hôpital Européen Georges Pompidou, Paris, France
    • ,
  • C. Balleyguier

      Affiliations

    • Institut Gustave Roussy, Villejuif, France
    • ,
  • J. Gautier

      Affiliations

    • Centre Léon Bérard, Lyon, France
    • ,
  • C. Celier

      Affiliations

    • Hôpital Saint-André, Bordeaux, France
    • ,
  • J. Medioni

      Affiliations

    • Hôpital Européen Georges Pompidou, Paris, France
    • ,
  • B. Escudier

      Affiliations

    • Institut Gustave Roussy, Villejuif, France
    • Corresponding Author InformationCorrespondence: Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France

Received 11 October 2008

References 

  1. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125
  2. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115
  3. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271
  4. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103
  5. Yagoda A, bi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983–1993. Semin Oncol. 1995;22:42
  6. Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma (Groupe Francais d'Immunotherapie). N Engl J Med. 1998;338:1272
  7. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet. 1994;7:85
  8. Figlin RA, Hutson TE, Tomczak P, Michaelson MD, Bukowski R, Negrier S, et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first line treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2008;26(suppl.):abstract 5024
  9. Escudier B: Overvew of clinical trials in RCC. Presented at European Society for Medical Oncology Congress, Stockholm, Sweden, September 12–16, 2008.
  10. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors (European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada). J Natl Cancer Inst. 2000;92:205
  11. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17:2530
  12. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9:327
  13. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099
  14. Dham A, Dudek AZ. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. J Clin Oncol. 2007;25(suppl.):18S;abstract 5106
  15. Hajdenberg J, Oberoi S, Cohen N, Kayaleh O, Harding D, Tseng J. Evaluation of VEGF targeted therapy efficacy in mRCC after sorafenib failure or intolerance. J Clin Oncol. 2007;25(suppl.):18S;abstract 15517
  16. Tamaskar I, Garcia JA, Elson P, Wood L, Mekhail T, Dreicer R, et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol. 2008;179:81
  17. Shaheen PE, Rini BI, Bukowski RM. Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports. Clin Genitourin Cancer. 2006;5:78
  18. Choueiri TK, Vaziri SA, Rini BI, Elson P, Bhalla I, Jaeger E, et al. Use of von-Hippel Lindau (VHL) mutation status to predict objective response to vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma (RCC). J Clin Oncol. 2009;25(suppl.):18S;abstract 5012
  19. Rini BI, George DI, Michaelson MD, Rosenberg J, Bukowski R, Sosman J, et al. Efficacy and safety of sunitinib malate in bevacizumab-refractory metastatic renal cell carcinoma (RCC). J Clin Oncol. 2006;24(suppl.):18S;abstract 4522
  20. Rini BI, Wilding G, Hudes G, Stadler W, Kim S, Tarazi JC, et al. Axitinib (AG013736; AG) in patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sorafenib. J Clin Oncol. 2007;25(suppl.):18S;abstract 5032

PII: S0022-5347(09)00540-0

doi: 10.1016/j.juro.2009.02.119

The Journal of Urology
Volume 182, Issue 1 , Pages 29-34 , July 2009

Article Tools

* Image Usage & Resolution